Today: 28 February 2026
Subscribe
Browse Category

ASX:TLX 11 December 2025 - 20 February 2026

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix (ASX:TLX) share price jumps 14% on 2026 revenue outlook — what moved the stock

Telix Pharmaceuticals shares closed up 14.2% at A$10.43 in Sydney after reporting 2025 revenue rose 56% to US$803.8 million and forecasting 2026 revenue of US$950 million to US$970 million. The company filed for European approval of its TLX101-Px brain cancer imaging agent earlier in the week. Telix ended 2025 with US$141.9 million in cash and posted a US$5.3 million pre-tax loss.
20 February 2026
··
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix Pharmaceuticals shares fell 7.7% to A$10.61 at Wednesday’s close after the company reported unaudited FY2025 revenue in line with guidance and noted early momentum for Gozellix. China’s drug regulator accepted the Illuccix application, triggering a formal review. Investors weighed ongoing U.S. regulatory developments and recent clinical trial results.
21 January 2026
··
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals shares fell 6.61% to A$11.73 on the ASX December 17, with volume at 6.36 million and a 52-week low of A$11.535. Nasdaq-listed shares dropped 6–7% in early U.S. trading. The company issued a statement confirming completion of Part 1 enrollment in its ProstACT Global Phase 3 study after market rumors. TLX591 has not received marketing authorization.
17 December 2025
···
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···
Go toTop